This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Delirium Caused by Donepezil: A Case Study

Toshiro Kawashima and Shigeto Yamada

Published: March 1, 2002

Article Abstract

Letter to the Editor

Sir: Donepezil, a centrally acting acetylcholinesterase inhibitor, is the first drug introduced in Japan for the symptomatic relief of cognitive impairment in patients with mildto- moderate Alzheimer’s disease. Some authors suggest that cholinomimetic treatment may also benefit certain behavioral problems associated with Alzheimer’s disease such as apathy, psychotic symptoms, and agitation. However, several adverse events related to donepezil have been reported so far, the most common being gastrointestinal disturbances due to cholinomimetic effects of donepezil.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 63

Quick Links: